Sanofi vs Soleno Therapeutics, Inc.: SG&A Expense Trends

Comparing SG&A trends: Sanofi vs Soleno Therapeutics

__timestampSanofiSoleno Therapeutics, Inc.
Wednesday, January 1, 201485650000002917513
Thursday, January 1, 201594960000007878291
Friday, January 1, 201695920000008366794
Sunday, January 1, 2017101640000006610381
Monday, January 1, 201899340000006556000
Tuesday, January 1, 201998830000006930000
Wednesday, January 1, 202093900000008758000
Friday, January 1, 2021955500000010806000
Saturday, January 1, 2022105390000009844000
Sunday, January 1, 20231076500000013481000
Monday, January 1, 20249183000000
Loading chart...

Infusing magic into the data realm

SG&A Expense Trends: Sanofi vs Soleno Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants and emerging players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Sanofi and Soleno Therapeutics, Inc. over the past decade, from 2014 to 2023.

Sanofi, a global leader, has consistently demonstrated robust financial management, with SG&A expenses showing a steady increase of approximately 26% over the period. In contrast, Soleno Therapeutics, Inc., a smaller entity, has seen its SG&A expenses surge by over 360%, reflecting its aggressive growth strategy.

This comparison highlights the contrasting financial strategies of a well-established pharmaceutical giant and a nimble, growth-oriented company. As the industry continues to evolve, these insights provide a window into the strategic priorities shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025